Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2025-10-16 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 85% confidence The document is an official announcement listing the company’s board members and committee roles, detailing the board and management structure. This aligns with Board/Management Information.
2025-10-16 English
Documents on Display
Regulatory Filings Classification · 95% confidence The document is a placeholder message from the Hong Kong Exchanges and Clearing Limited stating that the requested document has been removed by the issuer. Since it does not contain any substantive financial or corporate information and serves as a system-generated notice regarding a missing filing, it falls under the general regulatory announcement category.
2025-10-13 English
EXCESS APPLICATION FORM
Share Issue/Capital Change Classification · 88% confidence The document is an “Excess Application Form” for a rights issue of Immunotech Biopharm Ltd, under a prospectus dated 14 October 2025. It is used by shareholders to apply for excess rights shares on the basis of one rights share for every five existing shares, at a subscription price per share. This form is part of the share issuance/capital change documentation for the company’s fundraising via a rights issue. Therefore, it falls under Share Issue/Capital Change.
2025-10-13 English
RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY FIVE (5) EXISTING SHARES HELD ON THE RECORD DATE
Share Issue/Capital Change Classification · 90% confidence The document is a full prospectus for a Rights Issue by Immunotech Biopharm Ltd, featuring detailed terms of the offering, definitions, timetable, underwriting agreement, subscription procedures, and appendices with financial information. This is not merely an announcement or summary but the offering document itself for issuing new shares. Therefore it falls under “Share Issue/Capital Change” (SHA).
2025-10-13 English
PROVISIONAL ALLOTMENT LETTER
Share Issue/Capital Change Classification · 88% confidence The document is a Provisional Allotment Letter (PAL) relating to a rights issue, providing instructions and terms for subscribing to new shares. It is not an AGM material, financial report, or earnings release, but specifically pertains to a share issue/rights issue. Therefore, it fits “Share Issue/Capital Change” (SHA).
2025-10-13 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025
Share Issue/Capital Change Classification · 91% confidence The document is a monthly return filed to the HKEX under Listing Rule Chapter 19B detailing movements in authorised share capital, issued shares, treasury shares, share options, convertible bonds and related share issues. This is not a narrative report or earnings release but a regulatory update on share capital changes. It fits the “Share Issue/Capital Change” category (Code: SHA).
2025-10-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.